When a negative trial in ALS has a positive effect on research
N Atassi - The Lancet Neurology, 2018 - thelancet.com
In The Lancet Neurology, Albert Ludolph and colleagues3 report a double-blind, placebo-
controlled, multicentre clinical trial of rasagiline (1 mg/day) as an adjunct treatment to …
controlled, multicentre clinical trial of rasagiline (1 mg/day) as an adjunct treatment to …
Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial
Background: A neuroprotective effect of lithium in amyotrophic lateral sclerosis (ALS) has
been recently reported. We performed a multicenter trial with lithium carbonate to assess its …
been recently reported. We performed a multicenter trial with lithium carbonate to assess its …
Historical controls in ALS trials: a high seas rescue?
PD Donofrio, R Bedlack - Neurology, 2011 - AAN Enterprises
Historical controls in ALS trials | Neurology Skip to main content Skip to main content AAN.com
AAN Publications Author Center About the Journals Press Releases Go to homepage American …
AAN Publications Author Center About the Journals Press Releases Go to homepage American …
Treatment of pseudobulbar affect in ALS
RA Smith, BR Brooks - The Lancet Neurology, 2005 - thelancet.com
Man and Animals (1872):“certain brain diseases, such as hemiplegia, brain wasting and
senile decay, have a special tendency to induce weeping”. Along with tearfulness …
senile decay, have a special tendency to induce weeping”. Along with tearfulness …
Selecting promising ALS therapies in clinical trials
Riluzole is the only approved medication that extends survival for patients with amyotrophic
lateral sclerosis (ALS). While other potential neuroprotective agents have been evaluated in …
lateral sclerosis (ALS). While other potential neuroprotective agents have been evaluated in …
Edaravone for treatment of early-stage ALS
JS Mora - The Lancet Neurology, 2017 - thelancet.com
The Edaravone (MCI-186) ALS 19 Study Group1 reported on the safety and efficacy of
edaravone in a phase 3 study of patients with earlystage amyotrophic lateral sclerosis. The …
edaravone in a phase 3 study of patients with earlystage amyotrophic lateral sclerosis. The …
Riluzole for ALS: what is the evidence?
R Miller - Amyotrophic Lateral Sclerosis and Other Motor Neuron …, 2003 - Taylor & Francis
It has been eight years since the Food and Drug Administration approved riluzole as the
only drug of established value in slowing disease progression for patients with ALS. The …
only drug of established value in slowing disease progression for patients with ALS. The …
Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
L Lacomblez, G Bensimon, PN Leigh… - Lancet (London …, 1996 - europepmc.org
Background Amyotrophic lateral sclerosis (ALS) is a progressive disease with no effective
treatment. In an initial study, riluzole decreased mortality and slowed muscle-strength …
treatment. In an initial study, riluzole decreased mortality and slowed muscle-strength …
Clinical care of patients with amyotrophic lateral sclerosis
A Radunović, H Mitsumoto, PN Leigh - The Lancet Neurology, 2007 - thelancet.com
Although amyotrophic lateral sclerosis and its variants are readily recognised by
neurologists, about 10% of patients are misdiagnosed, and delays in diagnosis are …
neurologists, about 10% of patients are misdiagnosed, and delays in diagnosis are …